Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Show more
Location: 42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States | Website: https://quoinpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
4.143M
52 Wk Range
$5.01 - $54.95
Previous Close
$7.04
Open
$7.18
Volume
1,953
Day Range
$7.18 - $7.21
Enterprise Value
139.9M
Cash
7.79M
Avg Qtr Burn
-2.674M
Insider Ownership
0.20%
Institutional Own.
0.20%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QRX003 Details Netherton syndrome | Phase 3 Data readout | |
QRX003 Details Pediatric Netherton Syndrome (NS) | Phase 1/2 Data readout | |
QRX003 Details Pediatric Peeling skin syndrome | Phase 1 Data readout |